Official Title
Non-invasive Characterization of Systemic Microvascular Reactivity by Near-infrared Diffuse Optical Spectroscopy in COVID-19 Patients
Brief Summary

The purpose of this study is to characterize microvascular reactivity on the forearmmuscle using non-invasive near-infrared spectroscopy in critically ill COVID-19 patients,and to correlate its alterations with 28-day mortality in ICU COVID-19 patients.

Detailed Description

After giving consent to participate in the study, the subjects included in the study will
undergo a 15-minute measurement of tissue oxygen saturation (StO2) measured
non-invasively on the forearm by means of near-infrared spectroscopy (NIRS). Once a
baseline stable StO2 value is obtained, a provocative test, consisting of a transient
vascular occlusion, will be performed. The test will allow the obtention of a local
metabolic rate, and a StO2 recovery rate after the ischemic stimulus. This StO2 recovery
rate will be considered as a reflection of the endothelial health of the patient.

Patients will be studied as soon as possible after admission to the ICU, and followed-up
until ICU discharge or death.

Unknown status
COVID-19
Endothelial Function

Device: Vascular occlusion test

The ischemic challenge will consist in a standardized Vascular Occlusion Test (VOT), as
previously described in the literature. Briefly, a blood pressure cuff will be placed
proximal to the forearm, and rapidly inflated at 40 mmHg above systolic pressure, and
kept inflated during three minutes. Then the cuff will be rapidly deflated. The resulting
deoxygenation (DeO2) and reoxygenation (ReO2) slopes will be reported as change in O2
saturation over time.

Eligibility Criteria

Inclusion Criteria:

- Recent diagnosis of SARS-CoV2 infection

- Arterial hypoxemia and bilateral alveolar infiltrates, not explained by cardiac
dysfunction or fluid overload.

Exclusion Criteria:

- Severe peripheral vasculopathy

- Raynaud's syndrome

- Skin lesions or trauma in upper limbs interfering the placement of NIRS probe and/or
the occlusion tourniquet

- Deep venous thrombosis in the upper limbs

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Brazil
Mexico
Spain
United States
Locations

University of Texas Southwestern Medical Center
Dallas, Texas, United States

Hospital de Clinicas da UNICAMP
Campinas, Sao Paulo, Brazil

Hospital Das Clínicas University of Sao Paulo Medical School
Sao Paulo, Brazil

Hospital General de México
México, Mexico

Institut d'Investigació i Innovació Parc Taulí
Sabadell, Barcelona, Spain

Hospital Clínic i Provincial de Barcelona
Barcelona, Spain

Hospital Parc Salut Mar
Barcelona, Spain

Hospital Vall d'Hebron
Barcelona, Spain

Contacts

Jaume Mesquida, MD, PhD
+34 937231010 - 21155
jmesquida@tauli.cat

Jaume Mesquida, MD, PhD, Principal Investigator
Corporacion Parc Tauli

Corporacion Parc Tauli
NCT Number
Keywords
Covid-19
MeSH Terms
COVID-19